US Patent

US8372872 — Methods for concomitant treatment of theophylline and febuxostat

Method of Use · Assigned to Takeda Pharmaceuticals USA Inc · Expires 2031-09-08 · 5y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating a patient with gout who is also hyperuricemic by co-administering febuxostat and theophylline.

USPTO Abstract

Co-administration of febuxostat and theophylline to a hyperuricemic patient suffering from gout is disclosed.

Drugs covered by this patent

Uloric (FEBUXOSTAT) · Takeda

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1346`	—	Uloric
`U-1346`	—	Uloric

Patent Metadata

Patent number: US8372872
Jurisdiction: US
Classification: Method of Use
Expires: 2031-09-08
Drug substance claim: No
Drug product claim: No
Assignee: Takeda Pharmaceuticals USA Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.